Lacutamab has progressed to the Phase II TELLOMAK trial (NCT03902184), which is assessing the antibody's efficacy and safety in patients with advanced cutaneous T-cell lymphoma (CTLC). Lacutamab is under study in patients with mycosis fungoides and two other CTLC subtypes . . .

Get GEN Edge Today!

See More on the Edge

Continue reading this article and more
with a GEN Edge subscription

Start Your 30-Day Free Trial Now

Log In Join GEN Edge